Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million Phase Four unveils game changing engine for LEO Constellations Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958